Objectives: The browning of white adipose tissue (WAT) into beige has been proposed as a strategy to enhance energy expenditure to combat the growing epidemic of obesity. Research into browning strategies are hampered by the lack of sensitive, translatable, imaging tools capable of detecting beige fat mass non-invasively. [ 18 F]FEPPA uptake was likewise increased in inguinal WAT but showed no increase in BAT uptake due to stimulation over the same time course. Furthermore, inguinal WAT uptake was unaffected by pharmacological blockade, indicating that [
INTRODUCTION
Metabolically active brown adipose tissue (BAT) plays a significant role in metabolism and energy regulation [1e3] . While white adipose tissue (WAT) is responsible for energy storage, BAT is responsible for dissipating energy through the action of the uncoupling protein-1 (UCP1). In adults, increased BAT mass has been linked to lower body mass index leading to interest in the generation of de novo BAT as a potential therapeutic approach for obesity. Chemical stimulation with b3-adrenergic receptor (b3AR) agonists has been shown to induce browning in WAT but determination of the quantity and location of this new beige fat mass is a challenge [4] . Numerous imaging approaches have attempted to detect BAT [5] including magnetic resonance imaging (MRI), which relies on the unique chemical-shift of water-fat signals due to differences in morphology and chemical composition between WAT and BAT [6, 7] . However, reliable localization and quantification of beige tissue mass are hampered by poor sensitivity as the newly brown adipocytes are interspersed in WAT. Positron emission tomography (PET) is a uniquely sensitive imaging method and numerous tracers have been assessed for their ability to quantify BAT.
[ 18 F]FDG imaging is the current gold standard for imaging BAT and has been used to image beige fat, but detection is variable and dependent on stimulation through cold exposure or chemical stimulation [8, 9] . Other PET radiopharmaceuticals have been developed to quantify BAT mass including the cannabinoid receptor 1 imaging agent [ 18 F]FMPEP, the noradrenaline transporter agent [ 11 C]MRB, and the noradrenaline analogue [ 11 C]MHED; however, they have not been assessed for the ability to measure beige fat in vivo under unstimulated or thermoneutral conditions [10e13]. Both brown adipocytes and beige adipocytes have multilocular lipid droplets and possess abundant mitochondria that express UCP1 [14] whereas the surrounding white adipocytes only have one large lipid droplet and a relative paucity of mitochondria [13, 15] . This difference in mitochondrial abundance between WAT and beige fat suggests that an imaging agent able to quantify mitochondrial expression may be ideal for identifying beige fat mass. TSPO-18kDa (TSPO) is a five transmembrane domain protein located on the outer membrane of mitochondria and numerous radiopharmaceuticals have been developed to image TSPO expression, primarily for neuroinflammatory imaging [16] . Preclinical studies have shown that TSPO tracers can image BAT in vivo [17] and the TSPO tracer [
11 C]PBR28 has already been shown to identify BAT mass clinically [18] . The current study, however, is the first to attempt to use a TSPO tracer to detect the development of new beige fat deposits in WAT after b3AR agonist stimulation. 
MATERIALS AND METHODS

No
was azeotropically dried under a stream of nitrogen gas (250 ml/min) at 90 C with the addition of 1 Â 0.5 ml anhydrous acetonitrile. After cooling, a solution of the tosyl-precursor (5 mg, 9.4 mmol) in anhydrous acetonitrile (0.7 ml) was added before the reaction vial was sealed and heated at 90 C for a further 10 min. After cooling to room temperature, the crude reaction mixture was diluted with 3 ml HPLC mobile phase ( compound (1 mg/kg) was administered intraperitoneally daily for 7 days. b3-adrenergic receptor antagonist L-748,328 (1 mg/kg) was administered 1 h prior to imaging on Day 7 to determine basal binding.
PET-CT and MR imaging
The animals were imaged longitudinally 0, 1, 4, and 7 days after initiation of treatment using the Siemens Inveon PET-CT and the Mediso nanoscan 3T MR system using a modified version of the methodology described by Wang et al. [20] . Briefly, animals were imaged one hour after dosing with either CL-316,243 or vehicle, anesthetized using inhalational isoflurane anesthesia (maintained at 1.5% alveolar concentration) and injected with either [
18 F]FDG or 18 F] FEPPA (w10 MBq per animal) via the lateral tail vein. They were maintained heated and anaesthetized throughout the procedure. Static PET acquisitions were performed at 60e80 min post-injection and CT and T2 weighted fast spin echo MR scans were used to delineate fat depots (TR 3843 ms, TE 87.5 ms, matrix size 256 Â 256, 50.0 mm FOV, 1.0 mm slice thickness with no slice gap acquisition time 9 min). Animals were monitored for maintenance of body temperature and respiration rate during imaging studies using the Biovet physiological monitoring system. Post-analysis of reconstructed calibrated images were performed with FIJI and Amide software (version 10.3 Sourceforge). Uptake of radioactivity in the fat depots was determined by the placement of a volume of interest (VOI) around the interscapular BAT and inguinal WAT regions as delineated by CT and MR imaging. A VOI was also placed in the quadriceps muscle to provide reference tissue values.
Histology
On day 7, the inguinal fat tissues were dissected and fixed with 10% formalin, embedded in paraffin and sectioned. Sections were stained with hematoxylin and eosin (H&E) or were probed with an antibody for UCP1 (1:100, ab23841, Abcam) or TSPO-18kDa (1:100, ab109497, Abcam).
Statistical analysis
A two-way ANOVA with multiple Bonferroni post-test was performed using GraphPad Prism version 8.0.0 for Windows, GraphPad Software, San Diego, California USA, www.graphpad.com, p < 0.05 was considered statistically significant. Data are expressed as mean and error bars are expressed as AE SD.
RESULTS
Quantification of inguinal adipose browning with [
18 F]FDG and [ 18 F]FEPPA PET imaging PET imaging combined with CT was performed on days 0, 1, 4, and 7 post dosing with CL-316,243. As seen in Figure 1B, 
DISCUSSION
Recently there has been a plethora of research investigating ways to enhance the expression of thermogenes in WAT. The resulting beige tissue is hypothesized to combat obesity by reducing lipids stored within WAT and increasing energy expenditure [2, 3, 5, 21, 22] . These attempts to induce beige fat necessitate the development of sensitive and specific, translatable, imaging methodologies to accurately detect beige fat mass in vivo. Molecular imaging probes have been assessed for their ability to quantify beige fat across the spectrum of imaging with varying degrees of success. Optical imaging techniques including endogenous contrast and near infrared dyes have proven effective in preclinical models but clinical translation is limited [9,23e25] . Clinical techniques such as MRI, skin temperature measurements, nearinfrared spectroscopy, and contrast-enhanced ultrasound show the ability to accurately determine BAT mass or metabolic activity but are too insensitive to reliably detect de novo formation of beige fat [26, 27] . PET imaging provides a uniquely sensitive method for non-invasive assessment of browning. Currently only [
18 F]FDG uptake in stimulated beige fat has been well documented. [ 18 F]FDG uptake is linked to hexokinase 2 and UCP-1 (uncoupling protein 1) activity [9, 28] providing information on the metabolic activity of the beige adipocytes but little information on the number of beige adipocytes induced by stimulation. Beige adipocyte biogenesis in WAT is induced in response to multiple external stimuli including chronic cold, exercise and b3AR agonists.
These stimuli induce transdifferentiation of white adipocytes into beige adipocytes through a process involving the activation of PPARg (peroxisome proliferator-activated receptor-g) [29] and the PRDM16 (PRD1 domain containing protein 16) pathway [28] . Typically this conversion has been confirmed by measuring standard markers of brown adipocytes including UCP1 and mitochondrial expression. Beige adipocytes possess abundant mitochondria which express TSPO providing ample binding sites for [
18 F]FEPPA and the surrounding white adipocytes have few mitochondria [13, 15] , minimizing background uptake. Furthermore, [ 18 F]FEPPA measurement of mitochondrial TSPO expression is independent of activation, as shown by the b3AR
antagonist L-748,328 which had no effect on [ 18 F]FEPPA uptake in beige fat or BAT. TSPO radiopharmaceuticals seem well suited to detect beige fat mass independent of stimulation, however, this study has several limitations; firstly [
18 F]FEPPA uptake has not been assessed in completely unstimulated beige fat as expression is transient, reverting to the white phenotype within days of withdrawal of stimulation [30] . Secondly, we are unable to quantify the proportion of [ 18 F]FEPPA uptake that may be due to non-specific binding such as the increased vascularization associated with beige fat or infiltration of macrophages which express particularly high levels of TSPO. Also b3AR stimulation is a potent inducer of beige fat, useful in preclinical models, however, clinical approaches to induce beige fat, such as cold acclimation and exercise are less potent raising the question of how sensitive a measure of unstimulated beige fat might be in humans. It is not currently understood how many white adipocytes can undergo transdifferentiation to beige adipocytes, previous studies using cold stimulation in rodents have suggested up to 50% but this may be different in humans and dependent on adipocyte population or microenvironment [29, 31] 
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